# ProKidney Corp. (PROK)

> Source: Nexqual · https://nexqual.com/PROK · data as of 2026-10-23 16:53 UTC · cite as "Nexqual, ProKidney Corp. (PROK), nexqual.com/PROK" · informational, not investment advice.

**Price:** USD 1.4 (-2.10% today) · US market open, as of October 23, 2026 at 16:53 UTC; quotes may be delayed. Prev close 1.43 · day 1.37–1.44 · 52w 1.3–3.48 · market cap $559M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $818K, net income -$84.2M (-10288.4% margin), free cash flow -$160M (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $1.1M; 1 not under a Rule 10b5-1 plan ($1.1M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.67 on a 1–5 scale) (6 analysts), mean target USD 6.9 (range 1–12).
- Total return with dividends: 1Y -56.1% vs S&P 500 +14.6%; 5Y -85.9% vs S&P 500 +77.3%.
- Next earnings: 2026-11-09, EPS estimate USD -0.14, revenue estimate $125K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $0K | $0K | $76K | $893K | $818K |
| Operating income | -$55.1M | -$153M | -$152M | -$184M | -$165M | -$177M |
| Net income | -$55.1M | -$148M | -$35.5M | -$61.2M | -$69.0M | -$84.2M |
| EPS (diluted) | — | -$0.23 | — | — | — | — |
| Free cash flow | -$55.5M | -$78.9M | -$124M | -$156M | -$135M | -$160M |
| Operating margin | — | — | — | -241678.9% | -18477.8% | -21664.5% |
| Net margin | — | — | — | -80507.9% | -7725.2% | -10288.4% |
| Revenue growth | — | — | — | — | +1075.0% | — |
| Cash + short-term investments | $20.6M | $490M | $60.6M | $99.1M | $109M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 683.2x · FCF yield -28.58% · Earnings yield -15.06%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-18…2026-08-20 | Pereira Brian Jg | Director | 757,164 | $1.1M | 100% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.67 on a 1–5 scale), 6 analysts; mean target USD 6.9 (low 1, high 12).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -56.1% | -85.9% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -56.1% | -32.4% |
| Volatility (annualized) | 71.9% | 128.2% |
| Max drawdown | -58.7% (Oct 2025→Aug 2026) | -95.4% (Jul 2023→Mar 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 311.96 +1.34% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.05 -0.94% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.03 -0.81% · PRAX (Praxis Precision Medicines, Inc) USD 254.46 -1.72% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.17 -1.69% · ABVX (Abivax SA) USD 87.84 -2.65%

## More
Full page: https://nexqual.com/PROK · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in PROK's own 10-K filed 2026-03-18 (https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/prok-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Eli Lilly (LLY) | "We believe that our principal competitors include developers of SGLT2 inhibitors, including canagliflozin (marketed as Invokana® by companies including Janssen Pharmaceuticals, Inc.), dapagliflozin (marketed under the br…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.14 | $-0.14 | +2.3% | $124,600 | 4 |
| Next quarter (ends 2026-12-31) | $-0.14 | $-0.14 | +0.4% | $453,400 | 4 |
| Current fiscal year (ends 2026-12-31) | $-0.58 | $-0.54 | +7.3% | $529,000 | 4 |
| Next fiscal year (ends 2027-12-31) | $-0.61 | $-0.58 | +5.5% | $494,200 | 4 |